Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences (Q89313952)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29953902%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

title

Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29953902%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Stefano Aringhieri

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29953902%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Marco Carli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29953902%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Shivakumar Kolachalam

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29953902%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Valeria Verdesca

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29953902%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Enrico Cini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29953902%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Mario Rossi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29953902%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Peter J McCormick

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29953902%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Giovanni U Corsini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29953902%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Roberto Maggio

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29953902%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Marco Scarselli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29953902%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

publication date

25 June 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29953902%20AND%20SRC:MED&resulttype=core&format=json

Pharmacology & Therapeutics

3 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29953902%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

volume

192

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29953902%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

page(s)

20-41

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29953902%20AND%20SRC:MED&resulttype=core&format=json

Serotonin-dopamine interaction and its relevance to schizophrenia

3 April 2020

cites work

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

The fast-off hypothesis revisited: A functional kinetic study of antipsychotic antagonism of the dopamine D2 receptor

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Clozapine Reverses Phencyclidine-Induced Desynchronization of Prefrontal Cortex through a 5-HT(1A) Receptor-Dependent Mechanism.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Dopamine receptors: from structure to function

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Dopamine D2 and 5-hydroxytryptamine 5-HT(₂A) receptors assemble into functionally interacting heteromers.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Modulation of dopamine release by striatal 5-HT2C receptors

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Blockade of dopamine D₃ but not D₂ receptors reverses the novel object discrimination impairment produced by post-weaning social isolation: implications for schizophrenia and its treatment

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Chronic atypical antipsychotics, but not haloperidol, increase neurogenesis in the hippocampus of adult mouse.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Decreased dopamine D4 receptor expression increases extracellular glutamate and alters its regulation in mouse striatum

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

The Novel Antipsychotic Cariprazine (RGH-188): State-of-the-Art in the Treatment of Psychiatric Disorders

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Metabolic drug interactions with newer antipsychotics: a comparative review.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Quetiapine regulates FGF-2 and BDNF expression in the hippocampus of animals treated with MK-801.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Muscarinic m4 receptor activation by some atypical antipsychotic drugs

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Time-dependent changes and potential mechanisms of glucose-lipid metabolic disorders associated with chronic clozapine or olanzapine treatment in rats

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Dopamine D4 receptor, but not the ADHD-associated D4.7 variant, forms functional heteromers with the dopamine D2S receptor in the brain

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Identification of a serotonin/glutamate receptor complex implicated in psychosis

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Atypical antipsychotics and the relevance of glutamate and serotonin

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Muscarinic agonists and antagonists in schizophrenia: recent therapeutic advances and future directions

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Projections from basal forebrain to prefrontal cortex comprise cholinergic, GABAergic and glutamatergic inputs to pyramidal cells or interneurons

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Dopamine D2 and D4 receptor heteromerization and its allosteric receptor-receptor interactions

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Bitopertin: the good news and bad news

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain?

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Long-term therapeutic drug monitoring of clozapine and metabolites in psychiatric in- and outpatients

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Ultrastructural localization of the serotonin 2A receptor in dopaminergic neurons in the ventral tegmental area

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Altered dimerization of metabotropic glutamate receptor 3 in schizophrenia

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

A Phase II study of a histamine H₃ receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

The First Negative Allosteric Modulator for Dopamine D2 and D3 Receptors, SB269652 May Lead to a New Generation of Antipsychotic Drugs

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

A longitudinal study of alterations of hippocampal volumes and serum BDNF levels in association to atypical antipsychotics in a sample of first-episode patients with schizophrenia

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia?

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Mu opioid receptor regulation and opiate responsiveness

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Alpha2-adrenoceptor mediated co-release of dopamine and noradrenaline from noradrenergic neurons in the cerebral cortex

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Histamine in the nervous system

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Clozapine and haloperidol differentially alter the constitutive activity of central serotonin2C receptors in vivo

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

N-Substituted (2,3-dihydro-1,4-benzodioxin-2-yl)methylamine derivatives as D(2) antagonists/5-HT(1A) partial agonists with potential as atypical antipsychotic agents

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Update on typical and atypical antipsychotic drugs

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

N-methyl-D-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia: a critical review

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Clozapine efficacy in tardive dyskinesia in schizophrenic patients

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Differential effects of atypical and typical antipsychotic drugs on N-methyl-D-aspartate- and electrically evoked responses in the pyramidal cells of the rat medial prefrontal cortex

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Spotlight on amisulpride in schizophrenia

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Dopamine receptor occupancy in vivo: measurement using N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ)

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Direct and indirect interactions of the dopamine D₃ receptor with glutamate pathways: implications for the treatment of schizophrenia.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Mixed agonist-antagonist properties of clozapine at different human cloned muscarinic receptor subtypes expressed in Chinese hamster ovary cells

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Superwellness Program: a cognitive-behavioral therapy-based group intervention to reduce weight gain in patients treated with antipsychotic drugs

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Dopamine-glutamate interactions controlling prefrontal cortical pyramidal cell excitability involve multiple signaling mechanisms.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Antipsychotic drug actions on gene modulation and signaling mechanisms

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

D2/D3 dopamine receptor heterodimers exhibit unique functional properties

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

QTc prolongation, torsades de pointes, and psychotropic medications

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Therapeutic drug monitoring of atypical antipsychotic drugs.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Expression of 5-HT2A receptors in prefrontal cortex pyramidal neurons projecting to nucleus accumbens. Potential relevance for atypical antipsychotic action

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Bias Factor and Therapeutic Window Correlate to Predict Safer Opioid Analgesics

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Roles of G protein and beta-arrestin in dopamine D2 receptor-mediated ERK activation

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Desensitization of G protein-coupled receptors and neuronal functions

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Effects of the D3 and autoreceptor-preferring dopamine antagonist (+)-UH232 in schizophrenia

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Effects of Antipsychotic Administration on Brain Glutamate in Schizophrenia: A Systematic Review of Longitudinal 1H-MRS Studies

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Novel dimensions of D3 receptor function: Focus on heterodimerisation, transactivation and allosteric modulation

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Molecular mechanisms underlying synergistic effects of SSRI-antipsychotic augmentation in treatment of negative symptoms in schizophrenia

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

G protein-coupled receptor heterocomplexes in neuropsychiatric disorders.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Muscarinic acetylcholine receptors: signal transduction through multiple effectors.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Blonanserin extensively occupies rat dopamine D3 receptors at antipsychotic dose range.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Effect of clozapine on the dimerization of serotonin 5-HT(2A) receptor and its genetic variant 5-HT(2A)H425Y with dopamine D(2) receptor

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

The dopamine D3 receptor, a quarter century later.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Effects of age and gender on the serum levels of clozapine, olanzapine, risperidone, and quetiapine

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Experimental strategies for studying G protein-coupled receptor homo- and heteromerization with radioligand binding and signal transduction methods.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Chemistry-based molecular signature underlying the atypia of clozapine

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Interaction of dopamine D1 and NMDA receptors mediates acute clozapine potentiation of glutamate EPSPs in rat prefrontal cortex

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: correlation with receptor binding.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Modulation of nerve growth factor and choline acetyltransferase expression in rat hippocampus after chronic exposure to haloperidol, risperidone, and olanzapine

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Enlightening G-protein-coupled receptors on the plasma membrane using super-resolution photoactivated localization microscopy

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Functional selectivity of allosteric interactions within G protein-coupled receptor oligomers: the dopamine D1-D3 receptor heterotetramer.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Contributions of 5-HT(2C) receptors to multiple actions of central serotonin systems

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Antipsychotics for the management of psychosis in Parkinson's disease: systematic review and meta-analysis

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

The role of serotonin receptors in the action of atypical antipsychotic drugs

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Glutamate and dopamine in schizophrenia: an update for the 21st century

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Classics in chemical neuroscience: clozapine

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Tardive Dyskinesia Associated with Atypical Antipsychotics: Prevalence, Mechanisms and Management Strategies

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Clozapine for the treatment of schizophrenia

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

The potential role of dopamine D₃ receptor neurotransmission in cognition.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

The 'atypicality' of antipsychotics: a concept re-examined and re-defined

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Animal Models of Amphetamine Psychosis: Neurotransmitter Release from Rat Brain Slices

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Cariprazine, a dopamine D(3)-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Attention Must Be Paid: The Association of Plasma Clozapine/NDMC Ratio With Working Memory

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

The effect of a calorie-restricted diet on weight gain in short-term psychiatric inpatients receiving atypical antipsychotic medications

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Cariprazine: A Review in Schizophrenia

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Modulation of BDNF expression by repeated treatment with the novel antipsychotic lurasidone under basal condition and in response to acute stress

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Noradrenaline and Parkinson's disease

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Modulation of glutamate receptors in response to the novel antipsychotic olanzapine in rats

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Effect of muscarinic receptor agonists xanomeline and sabcomeline on acetylcholine and dopamine efflux in the rat brain; comparison with effects of 4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one (AC260584) and N-desmethylclo

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

5‐HT6 receptor antagonist SB‐271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

The tetrahydroisoquinoline derivative SB269,652 is an allosteric antagonist at dopamine D3 and D2 receptors

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

The fibroblast growth factor family: neuromodulation of affective behavior

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Different pharmacology of N-desmethylclozapine at human and rat M2 and M 4 mAChRs in neocortex

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Therapeutic Potential of Selectively Targeting the α2C-Adrenoceptor in Cognition, Depression, and Schizophrenia-New Developments and Future Perspective

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Homobivalent ligands of the atypical antipsychotic clozapine: design, synthesis, and pharmacological evaluation.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Fluoxetine and olanzapine have synergistic effects in the modulation of fibroblast growth factor 2 expression within the rat brain

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Role of 5-HT(2C) receptors in the control of central dopamine function

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

M4 muscarinic receptor knockout mice display abnormal social behavior and decreased prepulse inhibition.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Stimulation of 5-hydroxytryptamine (5-HT(2C) ) receptors in the ventrotegmental area inhibits stress-induced but not basal dopamine release in the rat prefrontal cortex

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Implication of the glutamate-cystine antiporter xCT in schizophrenia cases linked to impaired GSH synthesis

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Cognitive enhancing agents in schizophrenia and bipolar disorder

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Clozapine as the most efficacious antipsychotic for activating ERK 1/2 kinases: Role of 5-HT2A receptor agonism.

2 references

25 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1016/J.EURONEURO.2017.02.005

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Identification of dopamine D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatum

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

What has been learnt from study of dopamine receptors in Parkinson's disease?

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Histamine H3-receptor inverse agonists as novel antipsychotics

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Use of buspirone in the treatment of schizophrenia

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Clozapine ameliorates epigenetic and behavioral abnormalities induced by phencyclidine through activation of dopamine D1 receptor.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Beyond cAMP: The Regulation of Akt and GSK3 by Dopamine Receptors

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Effects of typical and atypical antipsychotics on human glycine transporters

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Clozapine is a potent and selective muscarinic M4 receptor agonist

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Clozapine. A novel antipsychotic agent

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, mul

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Medial prefrontal cortical D2 and striatolimbic D4 dopamine receptors: common targets for typical and atypical antipsychotic drugs.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Selective dopamine D3 receptor antagonists enhance cortical acetylcholine levels measured with high-performance liquid chromatography/tandem mass spectrometry without anti-cholinesterases

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Bitopertin in Negative Symptoms of Schizophrenia-Results From the Phase III FlashLyte and DayLyte Studies

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Selective visualization of rat brain 5-HT2A receptors by autoradiography with [3H]MDL 100,907.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Dopamine D4 receptors elevated in schizophrenia

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Dopamine D4-receptor modulation of cortical neuronal network activity and emotional processing: Implications for neuropsychiatric disorders

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Nature of Glutamate Alterations in Schizophrenia: A Meta-analysis of Proton Magnetic Resonance Spectroscopy Studies

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Functional μ-Opioid-Galanin Receptor Heteromers in the Ventral Tegmental Area.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Olanzapine counteracts reduction of brain-derived neurotrophic factor and TrkB receptors in rat hippocampus produced by haloperidol

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Clozapine, but not haloperidol, enhances glial D-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytes

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Pathogen-mediated NMDA receptor autoimmunity and cellular barrier dysfunction in schizophrenia

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Modulation of behavior by the histaminergic system: lessons from H(1)R-and H(2)R-deficient mice.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Ketamine enhances structural plasticity in mouse mesencephalic and human iPSC-derived dopaminergic neurons via AMPAR-driven BDNF and mTOR signaling

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Gender differences in tardive dyskinesia: a critical review of the literature

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Imaging glutamate in schizophrenia: review of findings and implications for drug discovery

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Activation of Muscarinic M1 Acetylcholine Receptors Induces Long-Term Potentiation in the Hippocampus.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Second-generation antipsychotic drugs, olanzapine, quetiapine, and clozapine enhance neurite outgrowth in PC12 cells via PI3K/AKT, ERK, and pertussis toxin-sensitive pathways

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist. I: Neurochemical and electrophysiological profile.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Pharmacogenetics as a tool in the therapy of schizophrenia

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Pharmacology of muscarinic acetylcholine receptor subtypes (m1-m5): high throughput assays in mammalian cells

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Structure and function of dopamine receptors

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Receptor-receptor interactions within receptor mosaics. Impact on neuropsychopharmacology

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Neuroleptic drugs in the human brain: clinical impact of persistence and region-specific distribution

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Prediction of working memory performance in schizophrenia by plasma ratio of clozapine to N-desmethylclozapine

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Phenotypical characterization of neurons expressing the dopamine D3 receptor in the rat brain.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Revealing G-protein-coupled receptor oligomerization at the single-molecule level through a nanoscopic lens: methods, dynamics and biological function.

2 references

25 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1111/FEBS.13577

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Molecular and cellular analysis of human histamine receptor subtypes.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Histamine H1 receptor occupancy by the new-generation antipsychotics olanzapine and quetiapine: a positron emission tomography study in healthy volunteers.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Predicting dopamine D₂ receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Clozapine modulates midbrain dopamine neuron firing via interaction with the NMDA receptor complex

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Neurotrophins: roles in neuronal development and function

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Effects of phencyclidine on auditory gating in the rat hippocampus and the medial prefrontal cortex

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

The dopamine D4 receptor: biochemical and signalling properties

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Fluvoxamine Inhibition and Carbamazepine Induction of the Metabolism of Clozapine

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Muscarinic mechanisms of antipsychotic atypicality

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Plasma levels of second-generation antipsychotics and clinical response in acute psychosis: a review of the literature

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Marked changes in signal transduction upon heteromerization of dopamine D1 and histamine H3 receptors

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Multiple D2 heteroreceptor complexes: new targets for treatment of schizophrenia

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Clinical outcome and plasma levels of clozapine and norclozapine in drug-resistant schizophrenic patients

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Asenapine induces differential regional effects on serotonin receptor subtypes

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl- d -aspartate receptor activity

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Dopamine D4 and D5 receptor gene variant effects on clozapine response in schizophrenia: replication and exploration.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Autoradiographic localization of 5-HT1A receptors in the post-mortem human brain using [3H]WAY-100635 and [11C]way-100635

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Metabotropic glutamate type 5, dopamine D2 and adenosine A2a receptors form higher-order oligomers in living cells

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Effects of clozapine on rat striatal muscarinic receptors coupled to inhibition of adenylyl cyclase activity and on the human cloned m4 receptor

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Pathophysiology and treatment of psychosis in Parkinson's disease: a review

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Second-generation antipsychotic effect on cognition in patients with schizophrenia--a meta-analysis of randomized clinical trials

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Regional, cellular, and subcellular variations in the distribution of D1 and D5 dopamine receptors in primate brain

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Clozapine interacts with the glycine site of the NMDA receptor: electrophysiological studies of dopamine neurons in the rat ventral tegmental area

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Hetero-dimerization of serotonin 5-HT(2A) and dopamine D(2) receptors

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Schizophrenia: more dopamine, more D2 receptors

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Disruption in prepulse inhibition after alpha-1 adrenoceptor stimulation in rats

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Antipsychotic drugs reverse the disruption in prefrontal cortex function produced by NMDA receptor blockade with phencyclidine.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Evidence for the use of pimavanserin in the treatment of Parkinson's disease psychosis

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Effects of selective activation of M1 and M4 muscarinic receptors on object recognition memory performance in rats

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Comparative localization of serotonin1A, 1C, and2 receptor subtype mRNAs in rat brain

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related CNS pathologies

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Treatment-Resistant Schizophrenia Patients Show Elevated Anterior Cingulate Cortex Glutamate Compared to Treatment-Responsive

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Pharmacogenetics of antipsychotics: recent progress and methodological issues

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Regulation of ABC transporters blood-brain barrier: the good, the bad, and the ugly

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Clozapine acts as an agonist at serotonin 2A receptors to counter MK-801-induced behaviors through a βarrestin2-independent activation of Akt

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Antipsychotic Drug-Induced Somnolence: Incidence, Mechanisms, and Management

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

The muscarinic system, cognition and schizophrenia

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Systemic chlorophenylpiperazine increases acetylcholine release from rat hippocampus-implication of 5-HT2C receptors

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Selective dopamine D4 receptor agonist (A-412997) improves cognitive performance and stimulates motor activity without influencing reward-related behaviour in rat.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Postsynaptic 5-hydroxytryptamine(1A) receptor activation increases in vivo dopamine release in rat prefrontal cortex

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Positive and negative symptoms: is their change related?

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Cognitive Impairment Induced by Delta9-tetrahydrocannabinol Occurs through Heteromers between Cannabinoid CB1 and Serotonin 5-HT2A Receptors

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Teaching old receptors new tricks: biasing seven-transmembrane receptors

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Dopamine receptor distribution in the rat CNS: elucidation using anti-peptide antisera directed against D1A and D3 subtypes

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Reversal of Phencyclidine-Induced Dopaminergic Dysregulation by N-Methyl-D-Aspartate Receptor/Glycine-site Agonists

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST).

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Tardive dyskinesia (syndrome): Current concept and modern approaches to its management

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Histamine H3 receptor antagonists/inverse agonists on cognitive and motor processes: relevance to Alzheimer's disease, ADHD, schizophrenia, and drug abuse

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Effects of 5-HT(6) receptor blockade on the neurochemical outcome of antidepressant treatment in the frontal cortex of the rat.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Estimating dopamine D₂ receptor occupancy for doses of 8 antipsychotics: a meta-analysis

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Co-expression and in vivo interaction of serotonin1A and serotonin2A receptors in pyramidal neurons of prefrontal cortex

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Dopamine D2 and D3 receptors in human putamen, caudate nucleus, and globus pallidus

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

The modulation of adult neuroplasticity is involved in the mood-improving actions of atypical antipsychotics in an animal model of depression

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Intracellular modulation of NMDA receptor function by antipsychotic drugs

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Antipsychotic drugs modulate Arc expression in the rat brain.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Elucidation of G-protein and β-arrestin functional selectivity at the dopamine D2 receptor

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Potentiation of amphetamine-induced changes in dopamine and 5-HT by a 5-HT(6) receptor antagonist

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Anticholinergic activity of 107 medications commonly used by older adults

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

The atypical antipsychotic clozapine selectively inhibits interleukin 8 (IL-8)-induced neutrophil chemotaxis

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Determinants of treatment response in first-episode psychosis: an 18F-DOPA PET study.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Dopamine D2-D3 receptor heteromers: pharmacological properties and therapeutic significance

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Evaluating an individualized lifestyle and life skills intervention to prevent antipsychotic-induced weight gain in first-episode psychosis.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Dopamine D2 receptors dimers: how can we pharmacologically target them?

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

The role of D1-D2 receptor hetero-dimerization in the mechanism of action of clozapine

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Evidence for co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

New concepts in pharmacological efficacy at 7TM receptors: IUPHAR review 2.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Differential effects of ziprasidone and haloperidol on immobilization stress-induced mRNA BDNF expression in the hippocampus and neocortex of rats

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

BDNF mRNA expression in rat hippocampus and prefrontal cortex: effects of neonatal ventral hippocampal damage and antipsychotic drugs

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Dopamine and serotonin receptor binding and antipsychotic efficacy

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Human prefrontal cortex: processing and representational perspectives

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Cell contact-dependent functional selectivity of β2-adrenergic receptor ligands in stimulating cAMP accumulation and extracellular signal-regulated kinase phosphorylation

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Serotonin 5-HT2C receptor homodimer biogenesis in the endoplasmic reticulum: real-time visualization with confocal fluorescence resonance energy transfer

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Schizophrenia, amphetamine-induced sensitized state and acute amphetamine exposure all show a common alteration: increased dopamine D2 receptor dimerization

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Effects of risperidone, clozapine and the 5-HT6 antagonist GSK-742457 on PCP-induced deficits in reversal learning in the two-lever operant task in male Sprague Dawley rats

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

The NMDA receptor 'glycine modulatory site' in schizophrenia: D-serine, glycine, and beyond

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Neuroprotection in Schizophrenia and Its Therapeutic Implications

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.PHARMTHERA.2018.06.012

Identifiers

DOI

10.1016/J.PHARMTHERA.2018.06.012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29953902%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29953902%20AND%20SRC:MED&resulttype=core&format=json